Here it is :)

H.C. Wainwright analyst Swayampakula Ramakanth started Corcept Therapeutics (CORT) with a Buy rating and $18 price target. While the Street has been primarily focused on the quarterly sales of Korlym and the outcome of the ongoing patent lawsuit case against Teva Pharmaceuticals (TEVA), the primary driver of Corcept's long-term value lies in its product pipeline, Ramakanth tells investors in a research note. The analyst believes that by 2030, all of Corcept's revenues will be derived from its pipeline products and could reach $1.06B per year.